SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myelo
Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myelo